5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Yahoo! Finance
specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety. Personalized approaches, like pharmacogenomics, identify patients most likely to benefit, enhancing treatment efficacy and adoption while accelerating drug development with cutting-edge technologies. New York, USA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- 5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety. Personalized approaches, like pharmacogenomics, identify patients most likely to benefit, enhancing treatment efficacy and adoption while accelerating drug development with cutting-edge technologies. DelveInsight's 5-HT2 Agonist Pipeline Insight 2025 report provides comprehensive global coverage of pipeli
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Cybin to Transfer U.S. Stock Exchange Listing to NasdaqBusiness Wire
- KILL Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq [Yahoo! Finance]Yahoo! Finance
- Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq [Yahoo! Finance]Yahoo! Finance
- Cybin to Transfer U.S. Stock Exchange Listing to NasdaqBusiness Wire
- Cybin (OTCMKTS:CYBN) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
CYBN
Earnings
- 11/14/25 - Miss
CYBN
Sec Filings
- 12/19/25 - Form F-X
- 12/19/25 - Form F-10
- 12/18/25 - Form 6-K
- CYBN's page on the SEC website